Pharmacology of Ramucirumab (Cyramza); Pharmacokinetics, Mechanism of Action, Uses, Effects скачать в хорошем качестве

Pharmacology of Ramucirumab (Cyramza); Pharmacokinetics, Mechanism of Action, Uses, Effects

Ramucirumab, marketed as Cyramza, is a monoclonal antibody used in the treatment of various cancers, including advanced gastric cancer, gastroesophageal junction adenocarcinoma, and non-small cell lung cancer. Here's an overview of its pharmacology: Mechanism of Action: VEGFR-2 Antagonist: Ramucirumab binds to vascular endothelial growth factor receptor 2 (VEGFR-2), blocking the binding of VEGF ligands (VEGF-A, VEGF-C, VEGF-D). This inhibits angiogenesis, the formation of new blood vessels that tumors need to grow and spread2. Pharmacokinetics: Administration: Given intravenously, ensuring direct delivery into the bloodstream. Half-Life: Approximately 8–12 days, allowing for dosing every 2 weeks. Metabolism: Broken down into smaller peptides and amino acids by proteolytic enzymes. Side Effects: Common side effects include hypertension, diarrhea, and fatigue. Serious adverse effects may include hemorrhage, arterial thromboembolic events, and gastrointestinal perforations. Clinical Applications: Approved for use in combination with other chemotherapy agents or as a monotherapy in specific cancer types #Ramucirumab